Investors

Epigenetics has the potential to improve human health through earlier disease diagnosis, improved patient stratification and the development of more effective, targeted therapies. Utilising disruptive discovery platforms and unrivalled epigenetics expertise, Cambridge Epigenetix is leading the epigenetic medicine revolution.

What is epigenetics?

Almost 15 years after the first sequencing of the human genome, we don’t yet fully understand the causes and progression of many important genetic diseases. Why? Because of epigenetics.

Epigenetics is the study of potentially heritable changes that are not caused by an alteration in the genetic code. Put simply, epigenetics regulates when and where genes are turned on or off. However, through changing the expression of our genes, epigenetic modifications can lead to a variety of diseases, including cancer.

Epigenetics impacts us at every stage of our lives. Our epigenome is constantly changing in response to our age, our environment and our lifestyle. However, unlike genetic changes, epigenetic changes can be readily reversed, meaning that, in the future we may be able to monitor someone’s epigenome and advise them on the lifestyle changes they need to implement to reduce or even reverse their risk of disease. In this way, understanding epigenetic modifications will revolutionise the way we detect and treat disease.

Why the excitement?

Epigenetics has the potential to improve human health through earlier diagnosis, improved patient stratification and the development of more effective, targeted therapies.

Epigenetic DNA modifications have been shown to be stable, tissue-specific and occur early in disease onset — sometimes before any detectable change in the DNA code. As a result, these modifications, which can be detected from accessible body fluids, represent an exciting target for diagnostic, prognostic and therapeutic applications.

Why Cambridge Epigenetix?

Cambridge Epigenetix is the premier epigenetic health company.

Contact Us

Utilising our disruptive epigenetics discovery platforms, we are developing the next generation of diagnostics and therapeutics. Our proprietary platforms accurately identify key epigenetic biomarkers - particularly the novel mark 5-hydroxymethylcytosine (5hmC) - and are underpinned by best-in-class technologies, strong IP, cutting-edge bioinformatics and a team of diagnostic and epigenetic sequencing experts.

Our leadership team brings significant expertise in technology development, epigenetics and biomarker development. The company has strong and secure funding from leading venture capital companies including GV (Google Ventures), Sequoia Capital, Syncona, New Science Ventures, and University of Cambridge.


Investing in the future

Cambridge Epigenetix's pioneering work and unrivaled capabilities in harnessing epigenetic insights will unleash the potential of precision medicine.

Our Investors

Roelof F. Botha

Sequoia Capital

Tom Hulme

GV

Somu Subramaniam

New Science Ventures

Alice Newcombe-Ellis

Ahren Innovation Capital

.

.


Our team of experts

Our experienced team comprises world-leading specialists in diagnostic development with core expertise in the identification of robust epigenetic signatures from liquid biopsy samples, including cell-free DNA (cfDNA) and circulating tumour DNA (ctDNA) as well as solid tissue biopsy.

Our Team

Find Out More

Interested in working with us, or want to know more about what we do?

CONTACT US